Claims
- 1. A method for inhibiting angiogenesis, the method comprising administering an effective amount of an anti-angiogenic agent that binds Gb3, such that angiogenesis is inhibited.
- 2. The method of claim 1, wherein the tissue is a tumor.
- 3. The method of claim 2, wherein the tumor is a cancer.
- 4. The method of claim 3, wherein the cancer is selected from the group consisting of breast cancer and ovarian cancer.
- 5. The method of claim 1, wherein the anti-angiogenic agent is a verotoxin.
- 6. The method of claim 5, wherein the verotoxin is verotoxin 1.
- 7. The method of claim 5, wherein the verotoxin is verotoxin 1 B-subunit.
- 8. The method of claim 5, wherein the verotoxin is verotoxin 2.
- 9 The method of claim 5, wherein the verotoxin is verotoxin 2c.
- 10. A method for treating a drug-resistant tumor, the method comprising administering to a subject in need thereof an effective amount of a verotoxin, such that the drug-resistant tumor is treated.
- 11. The method of claim 10, wherein the drug-resistant tumor is a cancer.
- 12. The method of claim 11, wherein the cancer is selected from the group consisting of breast cancer, testicular cancer, and ovarian cancer.
- 13. The method of claim 10, wherein the verotoxin is selected from the group consisting of verotoxin 1, verotoxin 1 B-subunit, verotoxin 2, and verotoxin 2c.
- 14. The method of claim 10, wherein the verotoxin is administered in a pharmaceutically-acceptable carrier.
- 15. A method for visualizing a blood vessel, the method comprising contacting the blood vessel with verotoxin such that verotoxin binds to the blood vessel; and
visualizing verotoxin bound to the blood vessel, such that the blood vessel is visualized.
- 16. The method of claim 15, wherein the visualizing step comprises contacting the bound verotoxin with a verotoxin-binding antibody.
- 17. The method of claim 16, wherein the verotoxin-binding antibody is labeled.
- 18. The method of claim 17, wherein the verotoxin-binding antibody is labeled with FITC.
- 19. The method of claim 15, wherein the verotoxin is selected from the group consisting of verotoxin 1, verotoxin 1 B-subunit, verotoxin 2, and verotoxin 2c.
- 20. A method for determining whether a tumor is multi-drug resistant, the method comprising:
determining the amount of Gb3 in a tumor sample; comparing the amount of Gb3 in the tumor sample with a preselected value; thereby determining whether the tumor is multi-drug resistant.
RELATED APPLICATION
[0001] This application claims priority to the U.S. Provisional Application Serial No. 60/046,640 entitled “Inhibition of Angiogenesis by Verotoxin” filed May 16, 1997.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60046640 |
May 1997 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09080027 |
May 1998 |
US |
Child |
09877399 |
Jun 2001 |
US |